8-K ·Filed Apr 16, 2026

MDXG

MIMEDX GROUP, INC.
BEARISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001376339-26-000021
8-K context-dependent: Items 5.02, 7.01
Actionable Insight ▼ Bearish

The cost reductions and executive departures suggest ongoing challenges in the Wound Care segment. Traders should monitor the upcoming quarterly conference call for more details on financial performance and whether these measures will improve profitability.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
MDXG ▲ +18.95% at T+60d
SHORT call ✗ call lost -18.95% · α vs SPY -11.90% · entry $3.43 → $4.08
Entry anchored
Apr 15, 03:59 PM ET
via exchange tick
T+1d
-0.29%
call +0.29% · α +1.51%
$3.42
settled 6mo ago
T+5d
-2.33%
call +2.33% · α +3.32%
$3.35
settled 5mo ago
T+20d
+2.62%
call -2.62% · α +3.19%
$3.52
settled 5mo ago
T+60d
+18.95%
call -18.95% · α -11.90%
$4.08
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

MiMedx Group announced a cost reduction initiative including the elimination of the Chief Operating Officer position and salary reductions for executives, citing slow recovery in the Wound Care market. The company expects $40 million in annualized savings and a one-time $4 million restructuring charge.

Key Facts

  • Ricci Whitlow departed as Chief Operating Officer
  • CEO Joe Capper's base salary reduced by 20%
  • Other named executive officers' base salaries reduced by 10%
  • Company expects $40 million in annualized savings
  • One-time restructuring charge of $4 million expected
  • Wound Care business recovering slowly from Medicare reimbursement reduction

Financial Impact

Annualized savings of $40 million with a one-time $4 million restructuring charge

operating expensesrestructuring chargeexecutive compensation

Risk Factors

  • Slow recovery in Wound Care business
  • One-time restructuring charge of $4 million
  • Potential negative impact on employee morale

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001376339-26-000021
Exhibit: ex-991restructuringpress.htm0001376339-26-000021
Document: 0001376339-26-000021-index-headers.html0001376339-26-000021
Document: 0001376339-26-000021-index.html0001376339-26-000021
Document: 0001376339-26-000021.txt0001376339-26-000021
4 reports for MDXG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MDXG — sortable, filterable
TypeNow
Jun 2, 2026
17w ago
Court Ruling
BULLISH ★ 5/10
$3.57 $4.42▲ +23.81%▲ +22.69%$4.59 (+28.57%)
Apr 29, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$3.36 $4.26▲ +26.79%▲ +23.68%$4.59 (+36.61%)
Apr 22, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$3.31 $4.30▲ +29.91%▲ +25.13%$4.59 (+38.67%)
Apr 16, 2026
24w ago
8-K
BEARISH ★ 7/10
$3.43 $4.08▼ −18.95%▼ −11.90%$4.59 (−33.82%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (65h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access